Physician profile
Candice E Rose
NPI 1437311354
$1,946.41
in general payments reported to CMS, 2019-2025
22 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $31.75 · 2021: $108 · 2022: $178 · 2023: $132 · 2024: $116 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $900 · Food and Beverage: $415 · Education: $59.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $900.00 |
| Food and Beverage | $415.00 |
| Education | $59.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $962.62 | 2022-2025 | Strensiq |
| Radius Health, INC. | $159.66 | 2019-2022 | |
| Pfizer INC. | $143.51 | 2019-2024 | |
| Horizon Therapeutics Plc | $108.28 | 2021-2022 | |
| Antares Pharma, INC. | $100.78 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Mannkind Corporation | $85.14 | 2019-2022 | |
| Kyowa Kirin, INC. | $59.70 | 2025 | |
| Amneal Pharmaceuticals LLC | $32.04 | 2025 | Unithroid |
| Novo Nordisk INC | $30.38 | 2025 | Sogroya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.50 | 2021-2023 | |
| Ascendis Pharma Endocrinology INC | $28.87 | 2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $27.47 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $22.38 | 2023 | Veozah |
| Daiichi Sankyo INC. | $22.02 | 2019 | |
| Neurocrine Biosciences, INC. | $21.10 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $20.60 | 2024 | Myalept |
| Medtronic Minimed, INC. | $18.95 | 2019 | |
| Ibsa Pharma INC. | $17.07 | 2024 | Licart, Tirosint |
| Sequel Med Tech, LLC | $16.46 | 2025 | Twiist |
| Shire North American Group INC | $14.39 | 2019 | |
| Halozyme INC | $13.18 | 2023 | |
| Abbvie INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.